## 1st Quarter of Fiscal 2018 Supplementary Materials

## Table of Contents

## Consolidated Basis

Statements of Income (Actual and Forecast) ..... 1 P
Sales Results and Plan by Product Line ..... 2 P
SG\&A and Other Income/Expenses (Actual and Forecast) ..... 3 P
Major Changes on Blance Sheets ..... $3 P$
Statements of Cash Flows ..... $4 P$
Non-Consolidated Basis
Statements of Income (Actual and Forecast) ..... 5 P
(Notes Concerning Forward-Looking Statements)
Projections throughout these materials are provided as areference for investors. They are based on estimates andforecasts, and shall not be regarded as pledges orguarantees. They shall be used on the fullacknowledgment that actual results may naturally differfrom projections.

Fiscal 2018 Statements of Income (Actual and Forecast, Consolidated)
First Quarter

| ter | Year-on-Year <br> Comparison |  |
| :---: | :---: | :---: |
| tal | Amount | \% |
| 0.0 | $\triangle 105$ | 98.8 |
| 59.5 | $\triangle 132$ | 97.6 |
| 0.5 | 26 | 100.7 |
| 33.9 | 291 | 113.3 |
| 6.5 | $\triangle 265$ | 82.5 |
|  | 3 |  |
|  | $\triangle 29$ |  |
| 6.4 | $\triangle 233$ | 84.5 |
|  | $\triangle 2,222$ |  |
|  | $\triangle 20$ |  |
| 0.5 | $\triangle 2,435$ | 34.3 |
|  | $\triangle 726$ | 33.9 |
|  |  |  |
|  | 0 |  |
| 8.5 | $\triangle 1,708$ | 34.5 |

## Second Quarter

$\neq$ millions, rounded down

|  | Sept. 2018 Plan |  | Sept. 2017 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 10,076 | 100.0 | 9,267 | 100.0 | 808 | 108.7 |
| Cost of Sales | 5,799 | 57.6 | 5,720 | 61.7 | 79 | 101.4 |
| Gross profit | 4,276 | 42.4 | 3,547 | 38.3 | 728 | 120.6 |
| SG\&A expenses | 2,664 | 26.4 | 2,231 | 24.1 | 433 | 119.4 |
| Operating income | 1,611 | 16.0 | 1,315 | 14.2 | 295 | 122.5 |
| Other income | 42 |  | 58 |  | $\triangle 16$ |  |
| Other expenses | $\triangle 24$ |  | 4 |  | $\triangle 28$ |  |
| Ordinary income | 1,677 | 16.7 | 1,369 | 14.8 | 308 | 122.5 |
| Extraordinary income | - |  | 1 |  | $\triangle 1$ |  |
| Extraordinary expenses | $\triangle 0$ |  | 0 |  | $\triangle 0$ |  |
| Income before income taxes and minority interests | 1,677 | 16.7 | 1,371 | 14.8 | 306 | 122.3 |
| Corporation tax, etc. | 496 |  | 392 |  | 104 |  |
| (Tax burden) | 29.6\% |  | 28.6\% |  |  |  |
| Minority interests | $\triangle 0$ |  | 0 |  | $\triangle 0$ |  |
| Net income | 1,181 | 11.7 | 979 | 10.6 | 201 | 120.6 |

## First Half

$\nexists$ millions, rounded down

|  | Sept. 2018 Interim Plan |  | Sept. 2017 Results |  | Year-on-Year Comparison |  | Sept. 2018 Initial Plan |  | Initial Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 19,130 | 100.0 | 18,427 | 100.0 | 702 | 103.8 | 19,130 | 100.0 | - | 100.0 |
| Cost of Sales | 11,120 | 58.1 | 11,173 | 60.6 | $\triangle 53$ | 99.5 | 11,120 | 58.1 | - | 100.0 |
| Gross profit | 8,010 | 41.9 | 7,254 | 39.4 | 755 | 110.4 | 8,010 | 41.9 | - | 100.0 |
| SG\&A expenses | 5,150 | 26.9 | 4,425 | 24.0 | 724 | 116.4 | 5,150 | 26.9 | - | 100.0 |
| Operating income | 2,860 | 15.0 | 2,829 | 15.4 | 30 | 101.1 | 2,860 | 15.0 | - | 100.0 |
| Other income | 90 |  | 103 |  | $\triangle 13$ |  | 90 |  | - |  |
| Other expenses | - |  | 57 |  | $\triangle 57$ |  | - |  | - |  |
| Ordinary income | 2,950 | 15.4 | 2,875 | 15.6 | 74 | 102.6 | 2,950 | 15.4 | - | 100.0 |
| Extraordinary income | - |  | 2,224 |  | $\triangle 2,224$ |  | - |  | - |  |
| Extraordinary expenses | - |  | 20 |  | $\triangle 20$ |  | - |  | - |  |
| Income before income taxes and minority interests | 2,950 | 15.4 | 5,078 | 27.6 | $\triangle 2,128$ | 58.1 | 2,950 | 15.4 | - | 100.0 |
| Corporation tax, etc. | 870 |  | 1,492 |  | $\triangle 622$ |  | 870 |  | - |  |
| (Tax burden) | 29.5\% |  | 29.4\% |  |  |  | 29.5\% |  |  |  |
| Minority interests | - |  | 0 |  | $\triangle 0$ |  | - |  | - |  |
| Net income | 2,080 | 10.9 | 3,586 | 19.5 | $\triangle 1,506$ | 58.0 | 2,080 | 10.9 | - | 100.0 |
| EPS (total shares) | $¥ 63.64$ |  | $¥ 109.73$ |  | - |  | $¥ 63.64$ |  |  |  |
| EPS (minus treasury shares) | $¥ 67.42$ |  | $¥ 114.55$ |  |  |  | $¥ 67.42$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury | 30,849,758 |  | 31,307,630 |  |  |  | 30,849,758 |  |  |  |

Fiscal 2018 Sales Results and Plan by Product Line (Consolidated)
First Quarter $\quad \neq$ millions, rounded down

|  | June 2018 1st Quarter Results |  | June 2017 1st Quarter Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 842 | 9.3\% | 888 | 9.7\% | $\triangle 46$ | 94.8\% |
| Surgical products | 7,947 | 87.8\% | 7,998 | 87.3\% | $\triangle 50$ | 99.4\% |
| Treatment products | 49 | 0.5\% | 48 | 0.5\% | 0 | 102.1\% |
| Others | 214 | 2.4\% | 224 | 2.5\% | $\triangle 9$ | 95.7\% |
| Total | 9,053 | 100.0\% | 9,159 | 100.0\% | $\triangle 105$ | 98.8\% |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 2,248 | 24.8\% | 2,312 | 25.2\% | $\triangle 64$ | 97.2\% |
| Other non-woven product | 311 | 3.4\% | 334 | 3.7\% | $\triangle 22$ | 93.3\% |
| Kit products | 5,339 | 59.0\% | 5,299 | 57.9\% | 39 | 100.7\% |
| Steel instruments | 48 | 0.5\% | 52 | 0.6\% | $\triangle 3$ | 93.4\% |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 69 |  | 52 |  | 17 |  |
| Others | 21 |  | 21 |  | $\triangle 0$ |  |

Second Quarter $\quad ¥$ millions, rounded down

|  | Sept. 2018 Plan |  | Sept. 2017 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 913 | 9.1\% | 900 | 9.7\% | 13 | 101.5\% |
| Surgical products | 8,872 | 88.1\% | 8,096 | 87.4\% | 775 | 109.6\% |
| Treatment products | 49 | 0.5\% | 48 | 0.5\% | 1 | 103.1\% |
| Others | 240 | 2.4\% | 222 | 2.4\% | 17 | 107.9\% |
| Total | 10,076 | 100.0\% | 9,267 | 100.0\% | 808 | 108.7\% |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 2,271 | 22.5\% | 2,298 | 24.8\% | $\triangle 26$ | 98.8\% |
| Other non-woven product | 328 | 3.3\% | 326 | 3.5\% | 1 | 100.4\% |
| Kit products | 6,150 | 61.0\% | 5,408 | 58.4\% | 741 | 113.7\% |
| Steel instruments | 121 | 1.2\% | 61 | 0.7\% | 59 | 195.9\% |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 80 |  | 49 |  | 30 |  |
| Others | 28 |  | 17 |  | 11 |  |

First Half
$¥$ millions, rounded down

|  | Sept. 2018 Interim Plan |  | Sept. 2017 Results |  | Year-on-Year <br> Comparison |  | Sept. 2018 Initial Plan |  | Initial Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Sterilization products | 1,755 | 9.2\% | 1,789 | 9.7\% | $\triangle 33$ | 98.1\% | 1,755 | 9.2\% | - | 100.0\% |
| Surgical products | 16,820 | 87.9\% | 16,094 | 87.3\% | 725 | 104.5\% | 16,820 | 87.9\% | - | 100.0\% |
| Treatment products | 99 | 0.5\% | 96 | 0.5\% | 2 | 102.6\% | 99 | 0.5\% | - | 100.0\% |
| Others | 455 | 2.4\% | 447 | 2.4\% | 7 | 101.7\% | 455 | 2.4\% | - | 100.0\% |
| Total | 19,130 | 100.0\% | 18,427 | 100.0\% | 702 | 103.8\% | 19,130 | 100.0\% | - | 100.0\% |
| Itemized surgical products |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 4,520 | 23.6\% | 4,610 | 25.0\% | $\triangle 90$ | 98.0\% | 4,520 | 23.6\% | - | 100.0\% |
| Other non-woven product | 640 | 3.3\% | 661 | 3.6\% | $\triangle 21$ | 96.8\% | 640 | 3.3\% | - | 100.0\% |
| Kit products | 11,490 | 60.1\% | 10,708 | 58.1\% | 781 | 107.3\% | 11,490 | 60.1\% | - | 100.0\% |
| Steel instruments | 170 | 0.9\% | 114 | 0.6\% | 55 | 149.0\% | 170 | 0.9\% | - | 100.0\% |
| Itemized external sales by subsidiary |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 150 |  | 101 |  | 48 |  | 150 |  | - |  |
| Others | 50 |  | 38 |  | 11 |  | 50 |  | - |  |

Sales Composition by Kit Treatment Category


SG\&A and Other Income / Expenses (Actual and Forecast, Consolidated)

SG\&A Expenses $\quad \neq$ millions, rounded down

|  | June 2018 1st Quarter Results | June 2017 1st Quarter Results | Year-on-Year Comparison |
| :---: | :---: | :---: | :---: |
| Packaging and transportation | 258 | 235 | 23 |
| Samples | 230 | 98 | 131 |
| Advertising | 11 | 26 | $\triangle 15$ |
| Personnel | 973 | 874 | 98 |
| Travel | 153 | 135 | 17 |
| Communication | 34 | 35 | $\triangle 0$ |
| Consumables | 22 | 26 | $\triangle 3$ |
| Taxes and public charges | 82 | 84 | $\triangle 1$ |
| Depreciation | 224 | 229 | $\triangle 5$ |
| Testing and research | 138 | 93 | 44 |
| Land and housing rent | 107 | 107 | 0 |
| Miscellaneous | 96 | 72 | 23 |
| Others | 152 | 173 | $\triangle 21$ |
| Total | 2,485 | 2,193 | 291 |

## Other Income/Expenses <br> $¥$ millions, rounded down

|  | June 2018 1st <br> Quarter Results | June 2017 1st <br> Quarter Results | Year-on-Year <br> Comparison |
| :--- | ---: | ---: | ---: |
| Interest received | 9 | 6 | 3 |
| Dividend received | 29 | 26 | 3 |
| (Total financial earnings) | 38 | 32 | 6 |
| Foreign exchange gain | - | 2 | $\triangle 2$ |
| Miscellaneous income | 9 | 9 | $\Delta 0$ |
| Total Other income | 47 | 44 | 3 |
| Foreign exchange loss | 10 | - | 10 |
| Miscellaneous losses | 13 | 53 | $\triangle 39$ |
| Total non-operating expenses | 24 | 53 | $\triangle 29$ |

## Major Changes on Balance Sheets / Statements of Cash Flows (Consolidated)

| Major Changes on Balance Sheets |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Balance at June 30, 2018 | Change |  | Balance at June 30, 2018 | Change |
| Current assets | 39,915 | $\triangle 2,534$ | Current liabilities | 7,286 | $\triangle 1,110$ |
| Cash and bank deposits | 18,284 | $\triangle 2,990$ | Notes and accounts payable | 4,925 | $\triangle 83$ |
| Notes and accounts receivable | 12,218 | 101 | Accrued expenses | 241 | 51 |
| Short-term investments | - |  | Long-term loans due within 1 yea |  |  |
| Inventories | 8,838 | 134 | Income taxes | 387 | $\triangle 547$ |
| Others | 574 | 219 | Allowance for employees' bonuse: | 170 | $\triangle 202$ |
|  |  |  | Payable notes for equipment | 237 | $\triangle 209$ |
|  |  |  | Reserve for disaster loss | - |  |
|  |  |  | Others | 1,324 | $\triangle 120$ |
| Fixed assets | 63,611 | $\triangle 92$ | Long-term liabilities | 3,845 | 152 |
| Property, plant and equipment |  |  | Others | 399 |  |
| Property, plant and equipment | 46,750 | $\triangle 1,141$ | Others | 3,445 | 152 |
| Buildings and structures | 22,945 | $\triangle 327$ | Total liabilities | 11,131 | $\triangle 958$ |
| Machinery, equipment and vehi | 12,454 | $\triangle 638$ | Total net assets | 92,395 | $\triangle 1,668$ |
| Land | 9,591 | $\triangle 26$ | Common stock | 7,123 |  |
| Construction in progress | 793 | $\triangle 103$ | Capital surplus | 8,336 |  |
| Others | 964 | $\triangle 44$ | Retained earnings | 76,091 | 411 |
| Intangibles | 2,960 | $\triangle 4$ | Treasury stock | $\triangle 6,017$ | $\triangle 2,257$ |
| Investments and others | 13,901 | 1,053 | Others | 6,862 | 178 |
| Investments securities | 12,036 | 488 |  |  |  |
| Others | 1,864 | 564 |  |  |  |
| Total assets | 103,527 | $\triangle 2,626$ | enuity | 103,527 | $\triangle 2,626$ |

* Comparison with end of previous fiscal year:

Equity ratio increased from $88.6 \%$ at the end of the previous fiscal year to $89.2 \%$.

## Statements of Cash Flows

$¥$ millions, rounded down

| I Operating activities | 873 | Income before income taxes and minority interests Depreciation expenses Income taxes paid | $\begin{aligned} & 1,272 \\ & 1,346 \\ & \triangle 881 \end{aligned}$ |
| :---: | :---: | :---: | :---: |
| IIInvesting activities | $\triangle 1,026$ | Purchase of tangible fixed assets Purchase of investment securities | $\begin{aligned} & \triangle 323 \\ & \triangle 538 \end{aligned}$ |
| IIIFinancing activities | $\triangle 2,740$ | Purchase of treasury stock Cash dividends paid | $\begin{array}{r} \triangle 2,271 \\ \triangle 487 \end{array}$ |
| IVEffect of exchange rate changes | $\triangle 96$ |  |  |
| Net changes in cash and cash equivalents | $\triangle 2,989$ |  |  |

Fiscal 2018 Statements of Income (Actual and Forecast, Non-Consolidated)
First Quarter $\quad ¥$ millions, rounded down

|  | June 2018 1st Quarter Results |  | June 2017 1st Quarter Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,962 | 100.0 | 9,085 | 100.0 | $\triangle 122$ | 98.7 |
| Cost of Sales | 5,459 | 60.9 | 5,619 | 61.9 | $\triangle 159$ | 97.2 |
| Gross profit | 3,503 | 39.1 | 3,465 | 38.1 | 37 | 101.1 |
| SG\&A expenses | 2,463 | 27.5 | 2,172 | 23.9 | 290 | 113.4 |
| Operating income | 1,039 | 11.6 | 1,293 | 14.2 | $\triangle 253$ | 80.4 |
| Other income | 42 |  | 48 |  | $\triangle 5$ |  |
| Other expenses | 31 |  | 59 |  | $\triangle 28$ |  |
| Ordinary income | 1,051 | 11.7 | 1,282 | 14.1 | $\triangle 230$ | 82.0 |
| Extraordinary income | - |  | 2,222 |  | $\triangle 2,222$ |  |
| Extraordinary expenses | 0 |  | 20 |  | $\triangle 20$ |  |
| Income before income taxes and minority interests | 1,051 | 11.7 | 3,484 | 38.4 | $\triangle 2,432$ | 30.2 |
| Corporation tax, etc. | 320 |  | 1,045 |  | $\triangle 724$ |  |
| (Tax burden) | 30.5\% |  | 30.0\% |  |  |  |
| Net income | 730 | 8.2 | 2,438 | 26.8 | $\triangle 1,707$ | 30.0 |
| EPS (total shares) | 22.36 |  | 74.61 |  |  |  |
| EPS (minus treasury shares) | 23.49 |  | 77.90 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 31,106,952 |  | 31,304,012 |  |  |  |

Second Quarter $\quad ¥$ millions, rounded down

|  | Sept. 2018 Plan |  | Sept. 2017 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 9,967 | 100.0 | 9,201 | 100.0 | 765 | 108.3 |
| Cost of Sales | 6,000 | 60.2 | 5,914 | 64.3 | 85 | 101.4 |
| Gross profit | 3,966 | 39.8 | 3,286 | 35.7 | 680 | 120.7 |
| SG\&A expenses | 2,636 | 26.5 | 2,211 | 24.0 | 425 | 119.2 |
| Operating income | 1,330 | 13.3 | 1,075 | 11.7 | 254 | 123.7 |
| Other income | 27 |  | 56 |  | $\triangle 29$ |  |
| Other expenses | $\triangle 21$ |  | 7 |  | $\triangle 28$ |  |
| Ordinary income | 1,378 | 13.8 | 1,125 | 12.2 | 253 | 122.5 |
| Extraordinary income | - |  | - |  | - |  |
| Extraordinary expenses | $\triangle 0$ |  | 0 |  | $\triangle 0$ |  |
| Income before income taxes and minority interests | 1,378 | 13.8 | 1,124 | 12.2 | 253 | 122.6 |
| Corporation tax, etc. | 419 |  | 337 |  | 81 |  |
| (Tax burden) | 30.4\% |  | 30.0\% |  |  |  |
| Net income | 959 | 9.6 | 787 | 8.6 | 172 | 121.9 |

First Half
$¥$ millions, rounded down

|  | Sept. 2018 Interim Plan |  | Sept. 2017 Results |  | Year-on-Year <br> Comparison |  | Sept. 2018 Initial Plan |  | Initial Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 18,930 | 100.0 | 18,286 | 100.0 | 643 | 103.5 | 18,930 | 100.0 |  | 100.0 |
| Cost of Sales | 11,460 | 60.5 | 11,534 | 63.1 | $\triangle 74$ | 99.4 | 11,460 | 60.5 |  | 100.0 |
| Gross profit | 7,470 | 39.5 | 6,752 | 36.9 | 717 | 110.6 | 7,470 | 39.5 |  | 100.0 |
| SG\&A expenses | 5,100 | 26.9 | 4,384 | 24.0 | 715 | 116.3 | 5,100 | 26.9 |  | 100.0 |
| Operating income | 2,370 | 12.5 | 2,368 | 13.0 | 1 | 100.1 | 2,370 | 12.5 |  | 100.0 |
| Other income | 70 |  | 105 |  | $\triangle 35$ |  | 70 |  | - |  |
| Other expenses | 10 |  | 66 |  | $\triangle 56$ |  | 10 |  | - |  |
| Ordinary income | 2,430 | 12.8 | 2,407 | 13.2 | 22 | 100.9 | 2,430 | 12.8 |  | 100.0 |
| Extraordinary income | - |  | 2,222 |  | $\triangle 2,222$ |  | - |  |  |  |
| Extraordinary expenses | - |  | 20 |  | $\triangle 20$ |  | - |  | - |  |
| Income before income taxes and minority interests | 2,430 | 12.8 | 4,608 | 25.2 | $\triangle 2,178$ | 52.7 | 2,430 | 12.8 |  | 100.0 |
| Corporation tax, etc. | 740 |  | 1,383 |  | $\triangle 643$ |  | 740 |  |  |  |
| (Tax burden) | 30.5\% |  | 30.0\% |  |  |  | 30.0\% |  |  |  |
| Net income | 1,690 | 8.9 | 3,225 | 17.6 | $\triangle 1,535$ | 52.4 | 1,690 | 8.9 |  | 100.0 |
| EPS (total shares) | 51.71 |  | 98.70 |  |  |  | 51.71 |  |  |  |
| EPS (minus treasury shares) | 54.78 |  | 103.03 |  |  |  | 54.78 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,849,758 |  | 31,307,630 |  |  |  | 30,849,758 |  |  |  |

